Adjuvant Transcatheter Arterial Chemoembolization Versus Adjuvant Systemic Chemotherapy for Hepatocellular Carcinoma
Status:
Withdrawn
Trial end date:
2017-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine that adjuvant systemic chemotherapy is superior to
adjuvant transcatheter arterial chemoembolization(TACE) in prolonging recurrence free
survival（RFS） in patients after radical resection of hepatocellular carcinoma.